Pharmawell Limited

	Page
Accountant's Report	1
Balance Sheet	2—3
Notes to the Financial Statements	4—7

Report to the directors on the preparation of the unaudited statutory accounts of Pharmawell Limited for the year ended 30 April 2025

To assist you to fulfil your duties under the Companies Act 2006, I have prepared for your approval the accounts of Pharmawell Limited which comprise the Profit and Loss Account, the Balance Sheet and the related notes, from the company’s accounting records and from information and explanations you have given us.

As a practising member of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html.

This report is made to the directors of Pharmawell Limited , as a body, in accordance with the terms of our engagement letter dated 01 June 2022. Our work has been undertaken solely to prepare for your approval the accounts of Pharmawell Limited and state those matters that we have agreed to state to the directors of Pharmawell Limited , as a body, in this report in accordance with the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharmawell Limited and its directors as a body for our work or for this report.

It is your duty to ensure that Pharmawell Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of Pharmawell Limited . You consider that Pharmawell Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Pharmawell Limited . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

Saii AG LLP

5 September 2025

Saii AG

Chartered Certified Accountants

Suite37/38 Marshall House, 124 Middleton Road

Morden

Surrey

SM4 6RW

Page 1

Page 2

Pharmawell Limited

Balance Sheet

As At 30 April 2025

Balance Sheet

Registered number: 10150935

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		480,467		520,506
Tangible Assets	5		5,863		7,817

			486,330		528,323
CURRENT ASSETS
Stocks		65,904		62,512
Debtors	6	112,534		131,373
Cash at bank and in hand		280,095		233,846

		458,533		427,731
Creditors: Amounts Falling Due Within One Year	7	(274,168 )		(261,751 )

NET CURRENT ASSETS (LIABILITIES)			184,365		165,980

TOTAL ASSETS LESS CURRENT LIABILITIES			670,695		694,303

Creditors: Amounts Falling Due After More Than One Year	8		(268,656 )		(311,034 )

NET ASSETS			402,039		383,269

CAPITAL AND RESERVES
Called up share capital			100		100
Profit and Loss Account			401,939		383,169

SHAREHOLDERS' FUNDS			402,039		383,269

Page 2

Page 3

Pharmawell Limited

Balance Sheet (continued)

As At 30 April 2025

For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mrs Dhara Patel

Director

5 September 2025

The notes on pages 4 to 7 form part of these financial statements.

Page 3

Page 4

Pharmawell Limited

Notes to the Financial Statements

For The Year Ended 30 April 2025

Notes to the Financial Statements

1. General Information

Pharmawell Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10150935 . The registered office is Lockyers Pharmacy, 252, Evelyn Street, Deptford, London, SE8 5BZ.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to profit and loss account over its estimated economic life of 20 years.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold	No Depreciation
Fixtures & Fittings	25% reducing balance
Computer Equipment	25% reducing balance

2.5. Leasing and Hire Purchase Contracts

Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.

2.6. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Page 4

Page 5

Pharmawell Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 April 2025

2.7. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

2.8. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

2.9. Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

2.10. Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.11. Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 5 (2024: 5)

Page 5

Page 6

Pharmawell Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 April 2025

4. Intangible Assets

	Goodwill
	£
Cost
As at 1 May 2024	800,779

As at 30 April 2025	800,779

Amortisation
As at 1 May 2024	280,273
Provided during the period	40,039

As at 30 April 2025	320,312

Net Book Value
As at 30 April 2025	480,467

As at 1 May 2024	520,506

5. Tangible Assets

	Land & Property
	Leasehold	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£
Cost
As at 1 May 2024	1	14,193	4,568	18,762

As at 30 April 2025	1	14,193	4,568	18,762

Depreciation
As at 1 May 2024	-	9,728	1,217	10,945
Provided during the period	-	1,116	838	1,954

As at 30 April 2025	-	10,844	2,055	12,899

Net Book Value
As at 30 April 2025	1	3,349	2,513	5,863

As at 1 May 2024	1	4,465	3,351	7,817

6. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	86,195	98,716
Other debtors	26,339	32,657

	112,534	131,373

Page 6

Page 7

Pharmawell Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 April 2025

7. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	146,317	135,630
Bank loans and overdrafts	54,940	54,940
Corporation tax	20,297	13,626
Other taxes and social security	1,252	1,138
Other creditors	51,362	56,417

	274,168	261,751

8. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Bank loans	268,656	311,034

9. Related Party Transactions

Mrs Dhara Vipinchandra Patel and Mr Cheten Patel are directors of the company.

At the end of the year, the amount owed by the company to the directors is £49,820.97 (2024:£54,005.07)

During the year, the company has declared a dividend of £0.00.(2024:£0.00)

10. Other information

Pharmawell Limited is a private company limited by shares and incorporated in England. Its registered office is:

Lockyer's Pharmacy

252 Evelyn Street

Deptford

England

SE8 5BZ

Page 7